CAR-T Therapy for Solid Tumors: Development of New Strategies

Samuel D. Bernal
2019 Trends in Immunotherapy  
The recent approval of two CAR-T therapies by US Food and Drug Administration (FDA) marks a very significant development in cell-based cancer immunotherapy. This milestone was demonstrated by the effectiveness of eradicating hematologic cancers using CD19-specific CARs. The success spurred development of immune cell therapies for other cancers, especially solid tumors. The generation of novel CAR constructs for these cancer types represents a major challenge in bringing the technology
more » ... echnology 'from-bench-to-bedside'.In this review, we outline some new technologies we have developed to equip CAR-T cells to enhance efficiency while decreasing toxicity of CAR-T therapies in solid tumors.
doi:10.24294/ti.v2.i3.1064 fatcat:rnn5337crrbvpf4dn6qgtfwktm